We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Sartorius, through its French unit Sartorius Stedim Biotech, has signed an agreement to acquire biotechnology company Polyplus for a total consideration of about €2.4bn. The French life science
British drugmaker GSK has signed an exclusive agreement with US-based biotechnology company Scynexis to license the latter’s antifungal therapy Brexafemme (ibrexafungerp tablets). Brexafemme is a novel oral glucan
Australian asset manager HMC Capital has signed an agreement with US-based healthcare investor Medical Properties Trust to acquire certain private hospitals in Australia for a total of A$1.20bn
Novartis and UK-based Bicycle Therapeutics have entered into a strategic collaboration to develop, manufacture and market bicyclic peptide (Bicycle) radio-conjugates (BRCs) for multiple oncology targets, mutually agreed by
Teva Pharmaceuticals announced that California’s Desert Oasis Healthcare (DOHC) system has implemented a respiratory patient monitoring programme based on its Digihaler System. The company designed the programme in
Dutch biopharmaceutical company Pharming has received the US Food and Drug Administration (FDA) approval for Joenja (leniolisib) to treat a rare type of primary immunodeficiency. Joenja is an
Japanese pharmaceutical company Takeda is set to invest around JPY100bn ($767m) to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan. PDTs are used to
The nutraceutical market is driven by several factors, including increasing consumer interest in health and wellness, growing demand for functional foods and dietary supplements, and the rising prevalence
Regeneron Pharmaceuticals has received expanded US Food and Drug Administration (FDA) approval for Evkeeza (evinacumab-dgnb) to treat an ultra-rare genetic condition in young children. Evkeeza is a fully
German biotechnology company BioNTech has entered into an exclusive worldwide license and collaboration agreement with clinical-stage biopharmaceutical company OncoC4. The collaboration aims to develop and market OncoC4’s monoclonal